— Why it moved
Why TVRD Stock Nearly Doubled Today — July 7, 2026
Phase 1 data for a next-gen STAT3 inhibitor hit a 5.7M-share float, and the move round-tripped by lunch.
What moved TVRD stock
Tvardi is a clinical-stage therapeutics company built around STAT3 inhibitors. It put out Phase 1 results for TTI-109, the follow-up to TTI-101 — cleaner tolerability, dose-proportional pharmacokinetics, some target-engagement markers. Real news, but it's a healthy-volunteer study, and the release says taking it further depends on regulatory clearance and funding. Funding is the word to notice at this market cap.
The mechanics
Float is 5.7M shares on a ~$19M cap, and about 70M shares traded, roughly 12 float turnovers. That structure turns any decent headline into a vertical candle. A momentum move, not a re-rating.
TVRD by the numbers
The alert window
Stock Pulse flagged it at 10:59 ET at $3.27, already up 60%+ on the session. The top was $3.86 at 11:13, fourteen minutes later, up 18%. Fourteen minutes, and the alert price already carried most of the day's gain.
How TVRD's move ended
It bled to $2.75 by early afternoon and finished at $3.10, 5% under the alert print. Peak to close was a 20% fade; anyone who bought after 11:15 ended the day red. The lead drug failed Phase 2 in IPF last October, which is where the $43.65 in that 52-week range comes from, and the latest 10-Q carries going-concern language, so dilution is the base case. On a going-concern balance sheet, a Phase 1 headline buys minutes of momentum, and the funding sentence in the press release is the part that prices the close.